5-Amino-1MQ vs NAD+
5-Amino-1MQ (Small-molecule NNMT inhibitor) and NAD+ (Cellular coenzyme (dinucleotide)) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | 5-Amino-1MQ | NAD+ |
|---|---|---|
| Compound class | Small-molecule NNMT inhibitor | Cellular coenzyme (dinucleotide) |
| Research category | Metabolic & Mitochondrial | Longevity & Cellular |
| Length (amino acids) | Not documented | Not documented |
| Molecular weight | ~159 g/mol (free base) | 663.43 g/mol (free acid) |
| Half-life | Not documented | Not documented |
| Origin | 5-Amino-1-methylquinolinium (5-Amino-1MQ) is a synthetic small-molecule quinolinium compound. It is not a peptide. It was identified as a cell-permeable inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). | Nicotinamide adenine dinucleotide (NAD+) is a naturally occurring coenzyme present in all living cells, first described in the early 20th century in the context of fermentation and cellular respiration. It is not a peptide but a dinucleotide composed of a nicotinamide moiety and an adenine moiety joined through ribose and phosphate groups. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How 5-Amino-1MQ works
5-Amino-1MQ inhibits NNMT, the enzyme that methylates nicotinamide using S-adenosylmethionine. By inhibiting NNMT, it is proposed to preserve cellular nicotinamide and NAD+ pools and reduce a metabolic sink associated with adipocyte expansion. In preclinical rodent studies, NNMT inhibition has been associated with reduced adipose tissue mass and altered cellular energy metabolism.
How NAD+ works
NAD+ functions as a central redox cofactor, cycling between its oxidized (NAD+) and reduced (NADH) forms to shuttle electrons in glycolysis, the citric acid cycle, and oxidative phosphorylation. Beyond redox chemistry, NAD+ is a required substrate for enzymes that consume it, including sirtuins (NAD+-dependent deacylases), poly(ADP-ribose) polymerases (PARPs) involved in DNA repair, and CD38. Cellular NAD+ levels have been reported to decline with age in various tissues, which is a focus of aging research. It is synthesized de novo from tryptophan and through salvage pathways from precursors such as nicotinamide, nicotinic acid, and nicotinamide riboside.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
5-Amino-1MQ
NAD+
What sets each apart
5-Amino-1MQ
Distinct from the peptides in this group: it is an orally-oriented small-molecule enzyme inhibitor acting on NNMT, rather than a receptor- or fragment-based peptide.
NAD+
Unlike the peptides in this category, NAD+ is a small-molecule coenzyme central to redox metabolism rather than a signaling peptide, and it is studied primarily via precursor supplementation.
Frequently asked questions
What is the mechanism of 5-Amino-1MQ?
5-Amino-1MQ competitively inhibits nicotinamide N-methyltransferase (NNMT) at its catalytic site. NNMT consumes S-adenosylmethionine (SAM) and methylates nicotinamide; inhibiting it is reported to raise intracellular SAM and NAD+ availability in adipocytes, shifting cells toward a more metabolically active, fat-oxidizing phenotype in preclinical models.
How does 5-Amino-1MQ differ from NAD+ boosters?
NAD+ precursors (like NR or NMN) supply substrate to raise NAD+ directly, whereas 5-Amino-1MQ works upstream by blocking NNMT, an enzyme that drains the methylation/SAM pool and is implicated in NAD+ salvage dynamics in fat. They target the same broad NAD+/SAM biology from different directions, which is why they are sometimes discussed together.
Is 5-Amino-1MQ a peptide?
No. 5-Amino-1MQ is a small-molecule NNMT inhibitor, chemically a methylquinolinium (5-amino-1-methylquinolinium) compound. It is often grouped with metabolic peptides in catalogs because of its fat-metabolism research context, but structurally it is a small molecule, not a peptide, and has no amino-acid sequence.
What is NAD+ and what is it studied for?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism, redox reactions, and as a substrate for sirtuins and PARP enzymes involved in DNA repair. It is studied in models of aging, mitochondrial function, metabolic decline, and neuroprotection, where tissue NAD+ levels fall with age. It is a naturally occurring coenzyme, not a peptide.
Is NAD+ a peptide?
No. NAD+ is a dinucleotide coenzyme composed of two nucleotides (one bearing adenine, the other nicotinamide) joined through phosphate groups, not a chain of amino acids. It is grouped in longevity research catalogs alongside peptides because of its role in aging and mitochondrial studies, but it is a distinct chemical class.
How does NAD+ differ from precursors like NMN and NR?
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors that cells convert into NAD+, whereas NAD+ is the finished coenzyme. Precursors are commonly studied as oral routes to raise intracellular NAD+, while NAD+ itself is studied via IV or subcutaneous routes in research settings. Direct cellular uptake of intact NAD+ is a subject of ongoing research.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.